Why Moderna, Inc. (MRNA) stock moved
Moderna, Inc. (MRNA) shares climbed 8.9% to $145.13 as of August 21, 2026, a significant gain from the prior close of $133.32. BestStocks flagged the session as a major change for MRNA. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MRNA climbed 8.9% to $145.13
Moderna rallied 7.18% to $142.89 as traders repositioned following a historic 177% surge earlier in the week sparked by positive late-stage melanoma vaccine trial results with Merck (reported by 247wallst.com and Yahoo Finance). The stock is experiencing volatile whipsaw trading with volume at 5.27x the time-adjusted average, driven by short-term traders and algorithmic funds resetting positions after Wednesday's breakout and Thursday's pullback; no fresh clinical or corporate data emerged on Friday. Earnings scheduled for November 5, 2026 (consensus EPS estimate: $-1.38); near-term watch for any regulatory or trial updates on the Merck melanoma vaccine partnership and sector sentiment shifts.
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 8.9% price move with conviction. Weighing against that: Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga); MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06. Wall Street's consensus price target sits at $106.44, implying -26.7% downside from $145.13. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (75/100). With earnings roughly 76 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $145.13, up $11.81 (+8.86%) from the previous close of $133.32. The session traded on 8.4× average volume (extreme), so the move carried above-average conviction. Over the past month the stock has ranged between $53.86 and $174.38, and it currently sits about 76% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $106.44, 26.7% below the recent $145.13. Over the past 90 days analysts logged 1 upgrade, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRNA line up.
The bullish case
- The Street's most bullish target is $245.00 (+68.8%).
- 1 analyst upgrade in the past 90 days, most recently William Blair to Outperform (2026-08-19).
- Material positive event.
- Strong 8.9% price move with conviction.
- Volume 8.4x average — institutional conviction.
The bearish case
- The consensus analyst price target of $106.44 sits 26.7% below the recent $145.13, so the average target sees limited room to run.
- The most bearish analyst target is $25.00 (-82.8%).
- Moderna reversed sharply after a historic surge driven by positive cancer-vaccine data, with the stock down 22.22% to $135.63 as a short squeeze unwind and profit-taking erased gains (Benzinga).
- MRNA moved -6.40% from its $57.54 open to a $53.86 close on 2026-08-06.
- Moderna, Inc. (MRNA) moved -3.01% from $58.00 to $56.26 on 2026-08-05.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MRNA
In-depth MRNA event analyses
Frequently asked questions about MRNA
Why did Moderna, Inc. (MRNA) stock move?
MRNA climbed 8.9% to $145.13. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did MRNA stock rise?
MRNA gained 8.86% ($11.81) versus the prior close of $133.32, last trading at $145.13 on 8.4× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-11-05 — about 76 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $106.44, about 26.7% below the current $145.13. Over the past 90 days, analysts recorded 1 upgrade, 10 maintains, and 0 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
